![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novavax Begins South African Efficacy Trial for COVID-19 Vaccine Hopeful
Novavax Begins South African Efficacy Trial for COVID-19 Vaccine Hopeful
![Novavax logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Novavax-logo.gif?t=1590614250&width=430)
August 18, 2020
Novavax announced that it has begun a phase 2b clinical trial of its COVID-19 vaccine candidate NVX-CoV2373 in South Africa.
The study will assess the efficacy of the Maryland-based biotech’s experimental vaccine in approximately 2,665 healthy patients, as well as its safety and immunogenicity in approximately 240 HIV-positive adults.
South Africa is experiencing a winter surge of COVID-19 disease, and the trial “has the potential to provide an early indication of efficacy, along with additional safety and immunogenicity data,” said Gregory Glenn, Novavax’s president of research and development.
Upcoming Events
-
21Oct